Previous research surrounding kidney disease and dementia demonstrated mixed and often conflicting results regarding the relationship between kidney function and the rate of dementia diagnosis. However, more recently, a study designed to evaluate the entire spectrum of kidney function and larger sample sizes indicated a strong relationship.
Below, we take a deep dive into this study, discussing how it compares to previous research surrounding kidney disease and dementia risk and how to address the limitations of current research.
According to a five-year study of a health care use cohort published in Neurology in May of 2021, both lower kidney function and steeper kidney function decline are associated with the development of dementia in older adults (≥65 years of age).
Because community-based reports surrounding the link between the estimated glomerular filtration rate (eGFR) and dementia risk have shown conflicting results, this study aimed to investigate on a large scale the connections between kidney function, kidney function decline, and dementia incidence.
eGFR is commonly used in clinical practice to assess kidney function, as this calculation can indicate how well the kidneys are filtering out specific agents produced by the body, such as creatinine and cystatin C.
The study utilized data from the Stockholm Creatinine Measurements (SCREAM) project, which included data from all residents receiving serum creatinine tests between the years 2006 and 2011. This enabled the researchers to analyze more than 90% of the total census population of individuals aged 65 and over (329,822 individuals). Exclusion criteria included any recorded history of dementia, missing information regarding age or sex, and undergoing kidney replacement therapy at cohort entry.
Study Outcome Measures:
The primary findings of this study were as follows:
Previous studies investigating kidney disease and dementia risk have had mixed findings, with some aligning with the results in the above study and others demonstrating conflicting findings.
For example, a Japanese study published in 2018 that analyzed 1,562 participants ≥60 years of age also observed a higher dementia risk in individuals with eGFR <60 mL/min. On the other hand, studies such as this French population-based Three-City study did not show increased dementia risks for individuals with eGFR <60 mL/min. However, these studies did find that the stratum of eGFR of 45 to 60 mL/min was associated with an increased incidence of vascular dementia.
The discrepancy between the findings may very well be due to the differing study designs and outcome measures. While some study designs involved screening, others involved health care extraction. Similarly, while some study outcome measures involved neuropsychological performance, others related to dementia diagnosis and/or drug dispensations.
For example, utilizing outcome measures such as scores from traditional neuropsychological assessments (e.g. the Mini-Mental State Exam) may not produce results granular enough to truly understand neurocognitive function and dementia risk. These assessments frequently produce noisy, highly variable results that lack the specificity and granularity to confidently draw conclusions on true neurocognitive function, let alone place them on a disease continuum.
Future studies surrounding kidney disease and dementia risk will likely require more robust outcome measures, assessing a breadth of neurocognitive domains at a highly detailed level. Future studies may also include higher frequency neurocognitive testing to better understand changes in neurocognitive function over time to enable researchers to create more robust associations between kidney function and dementia risk.
At Altoida, we are building the world’s-first Precision Neurology platform and app-based medical device—backed by 11 years of clinical validation—to accelerate and improve drug development, neurological disease research, and patient care.
By completing a 10-minute series of augmented reality and motor activities designed to simulate complex Activities of Daily Living on a smartphone or tablet, Altoida’s device extracts and provides robust measurements of neurocognitive function across 13 neurocognitive domains. Our device measures and analyzes nearly 800 multimodal cognitive and functional digital biomarkers. Through the collection of highly granular data from integrated smartphone or tablet sensors, Altoida’s device produces comprehensive neurocognitive domain scores. This data can be tracked longitudinally to reveal trends and patterns while flagging concerning ones.
Altoida is powering the next generation of research studies and clinical trials—our app-based medical device will provide researchers with the ability to increase the cost-efficiency, speed, and success of neurological disease research, from subject screening and monitoring to data analysis.
Our Precision Neurology platform and app-based medical device provide:
To learn more about kidney disease and dementia or about utilizing Altoida’s Precision Neurology platform for neurological disease research or clinical trials, contact us today.